The bumper rise is due to the rising demand for the drug and patients' gradual shift towards its higher dosage.
'AdFalciVax may offer advantages such as broader protection and a lower risk of immune evasion compared to existing single-stage malaria vaccines.'
Under this scholarship, first-year MBBS students from government colleges are eligible to receive monetary assistance of up to Rs 1,00,000 per year for a duration of up to 4.5 years, covering academic expenses incurred towards their MBBS degree.
Leading FMCG maker HUL said that it has received a demand notice of Rs 962.75 crore from the Income Tax Department and will go in for an appeal against the order. The notice relates to non-deduction of TDS on payment of Rs 3,045 crore to GlaxoSmithKline Consumer Healthcare (GSKCH) for the acquisition of Intellectual Property Rights of the Health Foods Drinks (HFD) business consisting of brands as Horlicks, Boost, Maltova, and Viva, according to a recent exchange filing.
Glaxo wants to obtain trademark rights for 'Volmax', the brand name of its respiratory medicine.
Glaxo Group 'neglected the duty of making timely disclosures' to the stock exchanges the BSE and the NSE, on various occasions, the Securities and Exchange Board of India said in its order.
The British pharma and consumer products maker had announced the open offer in November last year to raise its stake in its subsidiary to 75 per cent from 43.16 per cent at present.
Following its tie-up with Ranbaxy, pharma major GlaxoSmithKline said on Friday it was open to partnership with other Indian companies in the field of drug discovery and development, but it must be allowed to import molecules for research.
In a major relief to Glaxo SmithKline Pharmaceuticals Ltd, the Delhi high court on Tuesday protected its popular preparation under the brand name OSTOCALCIUM.
GlaxoSmithKline, the world's second biggest drug maker, said it was interested in acquisitions in India if the assets came at the right value.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
With the expectation of a big rise in the market for 'sensitive toothpastes' in the near term, GlaxoSmithKline (GSK), the largest company in the health food sector, has forayed into this category in India with its biggest global brand, Sensodyne Toothpaste. This has been launched across all metropolitan and Tier-I cities.
After flirting with 'indulgent' variants, Horlicks and Foodles have tasted success with their health and nutrition positioning.
The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.
The Cabinet Committee on Economic Affairs has approved the proposal of GlaxoSmithKline Pte Limited, Singapore for acquisition of 24.33 per cent shares in existing Indian subsidiary company of GSK Group.
GlaxoSmithKline has filed a lawsuit in a United States court against Dr Reddy's Laboratories alleging infringement of patent rights of a generic version of 'Imitrex' drug, used for the treatment of migraine.
The transaction is an all equity merger with 4.39 shares of HUL being allotted for every share in GlaxoSmithKline Consumer Healthcare India
GlaxoSmithKline Plc's anti-migraine drug brand, Imitrex, is turning out to be a good revenue earner for Indian generic companies.
For instance, two of GSKCH's OTC products -- Eno and Iodex -- command a household penetration of 9 and 10 per cent respectively in metro cities. GSKCH has already drafted a channel strategy for modern trade in collaboration with South African retailer Shoprite, where cross-category and checkout placements were identified as an opportunity to create a shopping occasion through impulse buying.
In a bid to speed up the litigation process, the leading home-grown pharma company Dr Reddy's Laboratories has withdrawn its challenge against GlaxoSmithKline's "compound" patent for anti-nausea drug Zofran.
GSK India, which has a turnover of Rs 1,751 crore (Rs 17.51 billion) and launched a cervical cancer drug, Cervarix, and breast cancer drug, Tykerb, last year, plans to launch Promacta, the first oral medication to increase platelet production for people with serious blood disorder, from its parent stable during the current year. Promacta is a relatively new drug, for which approval was given by the US Food and Drug Administration in November last year.
GlaxoSmithKline plc, Europe's biggest drugmaker, said on Wednesday that it was accelerating work on a possible vaccine against the deadly SARS virus but warned development would take years.
Dr Reddy's has reached an out-of-court settlement to launch the Glaxo-patented Imitrex, a migraine drug that had annual sales of $878 million as of March 31, 2006, in the US. Experts estimate Dr Reddy's may not get more than $8-$15 million sales in 2009 since majority of sales revenue has to be given to GSK, for allowing the launch the authorised generic version.
Pharma major Ranbaxy Laboratories on Thursday said it has scored a legal victory with a United States court ruling that its Cefuroxime Exetil product does not infringe upon the patent rights of GlaxoSmithKline.
The much-awaited merger of Burroughs Wellcome India Ltd with GlaxoSmithKline Pharmaceuticals Ltd in the country was approved by boards of both entities on Wednesday with a swap ratio of 14:10 shares.
A meeting of the board of directors of GlaxoSmithkline Consumer Healthcare Ltd is scheduled on January 31, 2003, inter alia, to consider and adopt the audited financial results for the year ended December 31, 2002.\n\n\n\n
Pharma major GlaxoSmithKline Pharmaceuticals Ltd has sold its Worli plot for Rs 107.6 crore (Rs 1.08 billion) to I-Ven Realty Ltd, a joint venture between ICICI Venture Funds Management Company Ltd and Oberoi Constructions.
GlaxoSmithkline Pharmaceuticals has posted a 52 per cent increase in net profit to Rs 35.09 crore for the first quarter ended March 31, 2003 as against Rs 23.02 crore for the corresponding quarter ended last fiscal.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances